CH645541A5 - Topisches, indomethacin enthaltendes arzneimittel. - Google Patents
Topisches, indomethacin enthaltendes arzneimittel. Download PDFInfo
- Publication number
- CH645541A5 CH645541A5 CH67181A CH67181A CH645541A5 CH 645541 A5 CH645541 A5 CH 645541A5 CH 67181 A CH67181 A CH 67181A CH 67181 A CH67181 A CH 67181A CH 645541 A5 CH645541 A5 CH 645541A5
- Authority
- CH
- Switzerland
- Prior art keywords
- polyethylene glycol
- indomethacin
- topical
- ether
- glycol
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title claims description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 title description 49
- 229960000905 indomethacin Drugs 0.000 title description 25
- 229940126601 medicinal product Drugs 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 19
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 11
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 11
- 239000002674 ointment Substances 0.000 claims description 8
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 230000009974 thixotropic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 9
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960001047 methyl salicylate Drugs 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 3
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 3
- 208000025978 Athletic injury Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- -1 polyethylene-ethylene Polymers 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002848 endoanesthetic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3006024A DE3006024C2 (de) | 1980-02-18 | 1980-02-18 | Topisches, Indomethacin enthaltendes Arzneimittel in Salbenform |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH645541A5 true CH645541A5 (de) | 1984-10-15 |
Family
ID=6094913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH67181A CH645541A5 (de) | 1980-02-18 | 1981-02-02 | Topisches, indomethacin enthaltendes arzneimittel. |
Country Status (11)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5815940A (ja) * | 1981-07-23 | 1983-01-29 | Eisai Co Ltd | ポリプレニル系化合物およびその製造方法ならびにそれを含有する医薬 |
| JPS59227818A (ja) * | 1983-06-09 | 1984-12-21 | Mitsubishi Chem Ind Ltd | ゲル状軟膏剤 |
| CH643138A5 (de) * | 1983-08-29 | 1984-05-30 | Mepha Ag | Indomethacin enthaltende, gelartige salbe. |
| WO1985004106A1 (fr) * | 1984-03-14 | 1985-09-26 | Corbiere Jerome | Ppocede de solubilisation de principes actifs et compositions pharmaceutiques ainsi obtenues |
| JPS60224638A (ja) * | 1984-04-23 | 1985-11-09 | Kao Corp | 経皮吸収促進剤およびこれを含有する外用剤 |
| JPH07112984B2 (ja) * | 1989-04-28 | 1995-12-06 | 久光製薬株式会社 | 泡状エアゾール製剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3624197A (en) * | 1969-09-04 | 1971-11-30 | Philip Schain | Water-soluble tissue infiltrating and embedding compositions |
| BE756975A (fr) * | 1970-06-09 | 1971-04-02 | Merck & Co Inc | Suppositoires |
| US4011313A (en) * | 1974-06-07 | 1977-03-08 | Syntex (U.S.A.) Inc. | Medicament preparations |
| JPS5320417A (en) * | 1976-08-10 | 1978-02-24 | Yamanouchi Pharmaceut Co Ltd | New composition of preparation for rectal application |
| GB2023000B (en) * | 1978-06-17 | 1982-10-13 | Kowa Co | Antinflammatory analgesic gelled ointments |
-
1980
- 1980-02-18 DE DE3006024A patent/DE3006024C2/de not_active Expired
-
1981
- 1981-01-29 GB GB8102674A patent/GB2069334B/en not_active Expired
- 1981-01-29 SE SE8100623A patent/SE447060B/sv not_active IP Right Cessation
- 1981-02-02 CH CH67181A patent/CH645541A5/de not_active IP Right Cessation
- 1981-02-03 NL NL8100503A patent/NL8100503A/nl not_active Application Discontinuation
- 1981-02-05 AT AT0051381A patent/AT373148B/de not_active IP Right Cessation
- 1981-02-17 FR FR8103119A patent/FR2475897A1/fr active Granted
- 1981-02-17 BE BE0/203809A patent/BE887541A/fr not_active IP Right Cessation
- 1981-02-18 ES ES500421A patent/ES8201826A1/es not_active Expired
- 1981-02-18 IT IT19824/81A patent/IT1136564B/it active
- 1981-02-18 JP JP56021633A patent/JPS6024764B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| BE887541A (fr) | 1981-06-15 |
| DE3006024C2 (de) | 1983-08-04 |
| SE447060B (sv) | 1986-10-27 |
| GB2069334B (en) | 1983-10-19 |
| DE3006024A1 (de) | 1981-08-20 |
| NL8100503A (nl) | 1981-09-16 |
| JPS56135413A (en) | 1981-10-22 |
| AT373148B (de) | 1983-12-27 |
| SE8100623L (sv) | 1981-08-19 |
| ES500421A0 (es) | 1982-01-16 |
| ES8201826A1 (es) | 1982-01-16 |
| IT8119824A0 (it) | 1981-02-18 |
| ATA51381A (de) | 1982-06-15 |
| JPS6024764B2 (ja) | 1985-06-14 |
| GB2069334A (en) | 1981-08-26 |
| FR2475897A1 (fr) | 1981-08-21 |
| FR2475897B1 (enrdf_load_stackoverflow) | 1984-02-10 |
| IT1136564B (it) | 1986-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69518729T2 (de) | Stickstoffoxyd abgebendes präparat zur behandlung von analen erkrankungen | |
| DE69421685T2 (de) | Entzündunghemmendes und analgetisches transdermales Gel enthaltend Ketoprofen | |
| DE3205504C2 (de) | Äußerlich anwendbares, Ibuprofen enthaltendes Arzneimittel | |
| DE69733086T2 (de) | Pharmazeutische zusammensetzungen welche kukui nuss öl enthalten | |
| DE69017654T2 (de) | Äusserlich anzuwendende analgetische lotion und verfahren zur herstellung. | |
| DE3751761T2 (de) | Penetrationsverbesserer für die transdermale Verabreichung von systemisch wirksamen Arzneimitteln | |
| DE69730688T2 (de) | Oral anzuwendende arzneizubereitung | |
| US4301145A (en) | Antiseptic skin cream | |
| DE2818553A1 (de) | Zusammensetzung zur behandlung von proliferativen hautkrankheiten | |
| DE69619052T2 (de) | Feste, wasserfreie, pharmazeutische Zubereitungen für vaginale Verwendung | |
| DE3879811T2 (de) | Pharmazeutische Zusammensetzung und ihre Verwendung. | |
| DE3302739A1 (de) | Oxidationsstabiles mittel | |
| DE2700448C2 (de) | Salbe zur Behandlung von Ulcus Cruris | |
| DE3006024C2 (de) | Topisches, Indomethacin enthaltendes Arzneimittel in Salbenform | |
| DE3418820A1 (de) | Arzneimittel fuer verdauungsgeschwuer | |
| EP0224868B1 (de) | Primycin enthaltendes kolloidales Grundgel, Verfahren zu dessen Herstellung, dieses Grundgel enthaltende pharmazeutische und pharmako-kosmetische Kompositionen | |
| EP0450123B1 (de) | Diclofenac-Natrium enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung | |
| DE2032914A1 (enrdf_load_stackoverflow) | ||
| DE3315463A1 (de) | Arzneimittel zur lokalen behandlung von psoriasis | |
| DE3316597C1 (de) | Gelförmige Zubereitung und ihre Verwendung als Pflegemittel | |
| DE69005113T2 (de) | Verwendung von peroxidlipiden zur herstellung eines arzneimittels zur behandlung von kreislaufinsuffizienz bei lokaler applikation. | |
| EP0383162A1 (de) | Verwendung einer Wirkstoffkombination zur Behandlung rheumatischer Erkrankungen | |
| DE2104851A1 (enrdf_load_stackoverflow) | ||
| EP0510318B1 (en) | Compositions for the topical treatment of burns | |
| DE4311048A1 (de) | Arzneimittel zur topischen Anwendung bei Hauterkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUE | Assignment |
Owner name: LICHTENSTEIN-PHARMAZEUTICA GMBH |
|
| PL | Patent ceased |